Fellowship · Sacramento, CA
Sponsored by University of California Davis Health · Director Anjlee Mahajan
Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 922 citations · Jonathan Wesley Riess
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 1,255 citations · Jonathan Wesley Riess
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 560 citations · Helen K. Chew
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 759 citations · Helen K. Chew
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 978 citations · Jonathan Wesley Riess
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 469 citations · Jonathan Wesley Riess
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 571 citations · Primo Nery Lara
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 390 citations · Helen K. Chew